Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Government College University, Faisalabad, Pakistan.
Department of Physics, Government College University Faisalabad, Faisalabad, Pakistan.
Daru. 2019 Dec;27(2):571-582. doi: 10.1007/s40199-019-00285-0. Epub 2019 Jun 21.
Clopidogrel (CLOP) is an antiplatelet drug with poor solubility in intestinal fluid, which limits its bioavailability after oral administration.
Current study focuses on developing site-specific floating microcarriers of CLOP using solvent diffusion evaporation method (SDEM) for retaining the drug in the stomach, thus improving the solubility of drug for better absorption.
SDEM was employed to formulate floating microcarriers using lipidic excipients, namely Gelucires (GL) to impart floating properties, in combination with ethyl cellulose as release retarding polymer.
Prepared particles were 169 ± 6 μm to 375 ± 13 μm in size, whilst encapsulation efficiency was ranged from 39.6 ± 0.60% to 96.50 ± 3.50%. Electron micrographs depicted discrete spherical microcarriers with porous structure, which amplified with increasing HLB value of GL and concentration of Eudragit E100. FTIR study confirmed absence of major drug polymer interactions while DSC and XRD studies revealed the presence of non-crystalline nature of drug in all formulations. Drug release at pH 1.2 enhanced more than 2-folds with increasing HLB value with 32% cumulative drug release for GL 43/01 and 69% for GL 50/13. More interestingly, adding various proportions of Eudragit E100 to GL 43/01 based formulations resulted in increased drug release as high as 71%. In all formulations, the drug release followed diffusion dependent process.
It is envisaged that this formulation strategy for CLOP is promising and could possibly be tested in future for its in vivo performance. Graphical abstract Lipid based floating microcarriers of clopidogrel.
氯吡格雷(CLOP)是一种在肠液中溶解度差的抗血小板药物,这限制了其口服后的生物利用度。
本研究旨在采用溶剂扩散蒸发法(SDEM)开发 CLOP 的定位释放型漂浮微球,以将药物保留在胃中,从而提高药物的溶解度,以更好地吸收。
采用 SDEM 以脂质赋形剂(即 Gelucires,GL)作为赋形剂来制备具有漂浮性能的漂浮微球,同时使用乙基纤维素作为缓释聚合物。
制备的颗粒粒径为 169±6μm 至 375±13μm,包封效率范围为 39.6±0.60%至 96.50±3.50%。电子显微镜照片显示出具有多孔结构的离散球形微球,随着 GL 的 HLB 值和 Eudragit E100 浓度的增加而放大。FTIR 研究证实了药物与聚合物之间不存在主要相互作用,而 DSC 和 XRD 研究表明所有制剂中药物均具有非晶态性质。在 pH 1.2 下,药物释放增加了 2 倍以上,随着 GL 43/01 的 HLB 值增加,累积药物释放率达到 32%,而 GL 50/13 的累积药物释放率达到 69%。更有趣的是,向基于 GL 43/01 的制剂中添加不同比例的 Eudragit E100 可使药物释放率高达 71%。在所有制剂中,药物释放均遵循扩散依赖过程。
可以预见,这种 CLOP 的制剂策略具有前景,未来可能会在体内性能方面进行测试。